Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.21037/jtd.2017.07.81 http://scihub22266oqcxt.onion/10.21037/jtd.2017.07.81 C5594185!5594185!28932572     free     free     free Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       J+Thorac+Dis 2017 ; 9 (8): 2650-9 Nephropedia Template TP {{tp|p=28932572|t=2017. Chronic lung allograft dysfunction phenotypes and treatment |pdf=|usr=}}{{28932572}} gab.com Text Chronic lung allograft dysfunction phenotypes and treatment JO: J Thorac Dis http://www.kidney.de/pget.php?&tw=1&pmid=28932572 #FOAvip Chronic lung allograft dysfunction (CLAD) remains a major hurdle limiting long-term survival post lung transplantation. Given the clinical heterogeneity of CLAD, recently two phenotypes of CLAD have been defined [bronchiolitis obliterans syndrome (BOS) vs. restrictive allograft syndrome (RAS) or restrictive CLAD (rCLAD)]. BOS is characterized by an obstructive pulmonary function, air trapping on CT and obliterative bronchiolitis (OB) on histopathology, while RAS/rCLAD patients show a restrictive pulmonary function, persistent pleuro-parenchymal infiltrates on CT and pleuroparenchymal fibro-elastosis on biopsies. Importantly, the patients with RAS/rCLAD have a severely limited survival post diagnosis of 6?18 months compared to 3?5 years after BOS diagnosis. In this review, we will review historical evidence for this heterogeneity and we will highlight the clinical, radiological, histopathological characteristics of both phenotypes, as well as their risk factors. Treatment of CLAD remains troublesome, nevertheless, we will give an overview of different treatment strategies that have been tried with some success. Adequate phenotyping remains difficult but is clearly needed for both clinical and scientific purposes. Twit Text FOAVip Chronic lung allograft dysfunction phenotypes and treatment ????J Thorac Dis http://www.kidney.de/pget.php?&tw=1&pmid=28932572 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=28932572 #FOAvip English Wikipedia <ref>{{Cite pmid|28932572}}</ref> Chronic lung allograft dysfunction phenotypes and treatment #MMPMID28932572 Verleden SE; Vos R; Vanaudenaerde BM; Verleden GM J Thorac Dis 2017[Aug]; 9 (8): 2650-9 PMID28932572show ga Chronic lung allograft dysfunction (CLAD) remains a major hurdle limiting long-term survival post lung transplantation. Given the clinical heterogeneity of CLAD, recently two phenotypes of CLAD have been defined [bronchiolitis obliterans syndrome (BOS) vs. restrictive allograft syndrome (RAS) or restrictive CLAD (rCLAD)]. BOS is characterized by an obstructive pulmonary function, air trapping on CT and obliterative bronchiolitis (OB) on histopathology, while RAS/rCLAD patients show a restrictive pulmonary function, persistent pleuro-parenchymal infiltrates on CT and pleuroparenchymal fibro-elastosis on biopsies. Importantly, the patients with RAS/rCLAD have a severely limited survival post diagnosis of 6?18 months compared to 3?5 years after BOS diagnosis. In this review, we will review historical evidence for this heterogeneity and we will highlight the clinical, radiological, histopathological characteristics of both phenotypes, as well as their risk factors. Treatment of CLAD remains troublesome, nevertheless, we will give an overview of different treatment strategies that have been tried with some success. Adequate phenotyping remains difficult but is clearly needed for both clinical and scientific purposes. äChronic lung allograft dysfunction phenotypes and treatment (epmc).pdf DeepDyve Pubget Overpricing